[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100589285":3},{"organization":4,"armGroups":7,"interventions":29,"overallOfficials":10,"centralContacts":47,"locations":54,"responsibleParty":69,"collaborators":10,"id":71,"slug":72,"hasResults":73,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":10,"eligibilityCriteria":77,"healthyVolunteers":73,"sex":78,"minAge":79,"maxAge":10,"enrollmentInfo":80,"targetDuration":10,"studyType":83,"phases":10,"briefSummary":84,"conditions":85,"keywords":87,"overallStatus":57,"whyStopped":10,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},{"fullName":5,"class":6},"Novartis","INDUSTRY",[8,14,19,24],{"label":9,"type":10,"description":11,"interventionNames":12},"Immunoglobulin A nephropathy (IgAN)-Iptacopan",null,"IgAN patients taking iptacopan and their caregivers",[13],"Other: Iptacopan",{"label":15,"type":10,"description":16,"interventionNames":17},"IgAN-atrasentan","IgAN patients taking atrasentan and their caregivers",[18],"Other: Atrasentan",{"label":20,"type":10,"description":21,"interventionNames":22},"IgAN-other treatment","IgAN patients taking other specific treatment and their caregivers",[23],"Other: Other treatment",{"label":25,"type":10,"description":26,"interventionNames":27},"IgAN-no treatment","IgAN patients taking none treatment and their caregivers",[28],"Other: No intervention",[30,35,39,43],{"type":31,"name":32,"description":33,"armGroupLabels":34,"otherNames":10},"OTHER","No intervention","Participants and their caregivers will report home reported outcomes (HRO) data on symptom burden to understand symptom variability and health-related quality of life (HRQoL).",[25],{"type":31,"name":36,"description":37,"armGroupLabels":38,"otherNames":10},"Other treatment","Participants and their caregivers will report HRO data on symptom burden and treatment usage to understand symptom variability and HRQoL.",[20],{"type":31,"name":40,"description":41,"armGroupLabels":42,"otherNames":10},"Iptacopan","Participants and their caregivers will report HRO data on symptom burden and treatment usage to understand symptom variability and HRQoL including those taking iptacopan.",[9],{"type":31,"name":44,"description":45,"armGroupLabels":46,"otherNames":10},"Atrasentan","Participants and their caregivers will report HRO data on symptom burden and treatment usage to understand symptom variability and HRQoL including those taking atrasentan.",[15],[48,53],{"name":49,"role":50,"phone":51,"phoneExt":10,"email":52},"Novartis Pharmaceuticals","CONTACT","+41613241111","novartis.email@novartis.com",{"name":49,"role":50,"phone":10,"phoneExt":10,"email":10},[55],{"facility":56,"status":57,"city":58,"state":59,"zip":60,"country":61,"countryCode":62,"cosmosGeoPoint":63,"geoPoint":68,"contacts":10},"Novartis Investigational site","RECRUITING","Boston","Massachusetts","02108","United States","US",{"type":64,"coordinates":65},"Point",[66,67],-71.05977,42.35843,{"lat":67,"lon":66},{"type":70,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100589285","a-mobile-app-based-study-to-evaluate-disease-burden-and-treatment-patterns-in-immunoglobulin-a-nephropathy-igan-in-the-us-100589285",false,"NCT06952426","A Mobile App-Based Study to Evaluate Disease Burden and Treatment Patterns in Immunoglobulin A Nephropathy (IgAN) in the US","A Mobile App-Based, Prospective, Observational Study to Evaluate Disease Burden and Treatment Patterns in Immunoglobulin A Nephropathy (IgAN) in the US","Inclusion Criteria:\n\n* Diagnosis of IgAN, regardless of symptom or treatment history\n* Adult aged 18 or older; adult caregiver to an adult patient aged 18 or older; or adult caregiver to a pediatric patient under 18 years of age\n* US-based with a proficient understanding of and ability to read the English language\n\nExclusion Criteria:\n\nNone","ALL","18 Years",{"count":81,"type":82},300,"ESTIMATED","OBSERVATIONAL","The study aims to longitudinally capture the full spectrum of symptoms, treatment utilization, and overall health-related quality of life (HRQoL) experienced by Immunoglobulin A nephropathy (IgAN) patients and their caregivers.",[86],"Immunoglobulin A Nephropathy",[88,89,40,90,91],"IgAN","HRQoL","atrasentan","Immunoglobulin A nephropathy","2025-06-12",{"date":94,"type":95},"2025-06-17","ACTUAL",{"date":97,"type":95},"2025-03-04",{"date":99,"type":82},"2025-06-30",{"name":49,"class":6},1]